Where you live can impact your cancer risk: a look at multiple myeloma in New York City

Kamath, Geetanjali R.; Renteria, Anne S.; Jagannath, Sundar; Gallagher, Emily J.; Parekh, Samir; Bickell, Nina A.

doi:10.1016/j.annepidem.2020.05.005

Cited by 11 publications

(23 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, increasing studies have suggested that ecosystems play a role in cancer incidence 30 , 31 . A study from the United States suggested that higher neighbourhood walkability was correlated with lower incidence of multiple myeloma incidence 32 . Green space is a significant factor in cancer research.…”

Section: Theoretical Framework and Literature Reviewmentioning

confidence: 99%

Exposome approach for identifying modifiable factors for the prevention of colorectal cancer

Chen

Liang

Huang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Previous studies have shown certain exposure factors (such as lifestyle and metabolism) are associated with colorectal cancer (CRC) events. However, the application of the exposome theoretical frame and the extent to which the exposome domain can modulate the risk of CRC remain unknown. Our study aimed to construct valid exposome measurements and examine the relationship between exposome counts and the risk of CRC. This study included 335,370 individuals in the UK Biobank. We used exploratory factor analysis to identify a valid construct of exposome factors. We then summed the exposome counts within each domain. Cox proportional hazard models were used to estimate the hazard ratios and 95% confidence intervals of CRC risk related to the exposome factors and counts. During an 8.69 year median follow-up, 10,702 CRC cases were identified. Five domains were extracted from 12 variables, including ecosystem, lifestyle, tobacco and alcohol use, social economics, and social support. The Cox model results showed that the ecosystem was positively related to the reduced CRC risk (HR = 0.970; 95% CI 0.952–0.989). Similar results were also found among the domains of healthy lifestyles (HR = 0. 889; 95% CI 0.871–0.907), and no tobacco and alcohol use (HR = 0.892; 95% CI 0.876–0.909). The disadvantageous social economic (HR = 1.081; 95% CI 1.058–1.105) and insufficient social support domains (HR = 1.036; 95% CI 1.017–1.056) were associated with an increased risk of CRC. Similar risk trends were also observed across the exposome count groups with CRC incidence. Our findings suggest that certain exposure domains are related to the incidence of CRC. Ecosystem, lifestyle, and social factors can be incorporated into prediction models to identify individuals at high risk of CRC.

show abstract

Section: Theoretical Framework and Literature Reviewmentioning

confidence: 99%

Exposome approach for identifying modifiable factors for the prevention of colorectal cancer

Chen

Liang

Huang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Multiple myeloma is marked by disparities in terms of incidence, treatment, and outcomes. Disparities in multiple myeloma incidence have been described with respect to race and ethnicity, 53,55,59,63,67,77,80,95,105 socioeconomic status, 63,80,82 and geography. 53,80,105 For example, multiple myeloma incidence rates are reported as being double for African American populations compared with White populations in the US.…”

Section: Description Of Included Publicationsmentioning

confidence: 99%

“…Disparities in multiple myeloma incidence have been described with respect to race and ethnicity, 53,55,59,63,67,77,80,95,105 socioeconomic status, 63,80,82 and geography. 53,80,105 For example, multiple myeloma incidence rates are reported as being double for African American populations compared with White populations in the US. 80 However, some studies suggest that racial and ethnic disparities in incidence may be better explained by disparities in socioeconomic status.…”

Section: Description Of Included Publicationsmentioning

confidence: 99%

“…53,80,105 For example, multiple myeloma incidence rates are reported as being double for African American populations compared with White populations in the US. 80 However, some studies suggest that racial and ethnic disparities in incidence may be better explained by disparities in socioeconomic status. 63 As 1 study suggests, differences in multiple myeloma incidence at different ages among different groups could affect the type of treatment received.…”

Section: Description Of Included Publicationsmentioning

confidence: 99%

“…71,74,77,91 With respect to supply, some authors have argued that considerations of distributive and procedural justice may arise where the demand for CAR T-cell therapies exceeds manufacturing and administration capacities, which may be constrained by access to highly trained personnel and facilities capable of collecting, shipping, and handling cells, as well as administering the therapy. 101 Finally, disparities in multiple myeloma outcomes have been described with respect to age 53,55,66,79,81,87 ; race and ethnicity [53][54][55]58,65,71,73,75,[79][80][81]86,88,92,96 ; socioeconomic status 52,66,71,75,80,83,85,86,88,96,100,103,104 ; geography, proximity, and access to treatment centres 52,55,79,80,84,97 ; and insurance status. 66,79,...…”

Section: Description Of Included Publicationsmentioning

confidence: 99%

See 2 more Smart Citations

Idecabtagene Vicleucel (Abecma)

Team¹

2022

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses idecabtagene vicleucel (Abecma), cell suspension in 1 or more patient-specific infusion bag(s); target dose of 450 × 106 CAR T cells, within a range of 275 × 106 to 520 × 106 CAR T cells; for IV infusion. Indication: For the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody, and who are refractory to their last treatment.

show abstract

Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Health disparities in multiple myeloma (MM) disproportionately affect minorities. Characterization of health disparities encountered by Hispanic Americans with MM is necessary to identify gaps and inform future strategies to eliminate them. We performed a systematic review of publications that described health disparities relevant to Hispanic Americans with MM through December 2021. We included all original studies which compared incidence, treatment, and/or outcomes of Hispanic Americans with other ethnic groups. Eight hundred and sixty-eight articles were identified of which 22 original study articles were included in our systematic review. The number of publications varied over time with the highest number of studies (32%) published in 2021. Most of the published studies (59%) reported worse outcomes for Hispanic Americans with MM compared to other ethnic groups. There is growing evidence that Hispanic Americans with MM are facing a multitude of disparities that require immediate attention and solutions.

show abstract

Where you live can impact your cancer risk: a look at multiple myeloma in New York City

Cited by 11 publications

References 52 publications

Exposome approach for identifying modifiable factors for the prevention of colorectal cancer

Exposome approach for identifying modifiable factors for the prevention of colorectal cancer

Idecabtagene Vicleucel (Abecma)

Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review

Contact Info

Product

Resources

About